Patents by Inventor Oleksandr Buzko

Oleksandr Buzko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Calcium flux agonists and methods therefor
    Patent number: 9750805
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: September 5, 2017
    Assignee: Nant Holdings IP, LLC.
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Patrick Soon-Shiong, Anne-Laure Le Ny, Oleksandr Buzko
  • Compositions and methods of targeting mutant K-Ras
    Patent number: 9687491
    Abstract: The invention relates to a method of modeling K-Ras proteins with one or more mutations that result in constitutive activity, and identifying compounds that inhibit interactions among activated K-Ras proteins and their upstream and downstream effectors.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: June 27, 2017
    Assignee: NantBioscience, Inc.
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • SMALL MOLECULE INHIBITORS OF INFLUENZA A RNA-DEPENDENT RNA POLYMERASE
    Publication number: 20170128450
    Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
    Type: Application
    Filed: July 18, 2016
    Publication date: May 11, 2017
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure LeNy, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Calcium Flux Agonists And Methods Therefor
    Publication number: 20170128568
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Application
    Filed: September 14, 2016
    Publication date: May 11, 2017
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Patrick Soon-Shiong, Anne-Laure Le Ny, Oleksandr Buzko
  • Compositions And Methods For Viral Cancer Neoepitopes
    Publication number: 20170028044
    Abstract: Methods and compositions for preparation and use of recombinant viruses or other recombinant expression systems are presented in which neoepitopes are first identified in a patient- and cancer-specific manner and then further filtered by HLA-match to the patient. Selected neoepitopes are then expression using sequence elements that direct the expressed neoepitope to the HLA-type (MHC-I and/or MHC-II subtype) that has desirable affinity to the filtered neoepitope.
    Type: Application
    Filed: October 12, 2016
    Publication date: February 2, 2017
    Inventors: Patrick Soon-Shiong, Stephen Charles Benz, Andrew Nguyen, Shahrooz Rabizadeh, Kayvan Niazi, Oleksandr Buzko, Jay Gardner Nelson
  • Calcium flux agonists and methods thereof
    Patent number: 9463184
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: October 11, 2016
    Assignee: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Patrick Soon-Shiong, Anne-Laure Le Ny, Oleksandr Buzko
  • Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
    Patent number: 9422291
    Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: August 23, 2016
    Assignee: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure LeNy, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
    Patent number: 9315464
    Abstract: Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5? and 3?-UTR sequences of the viral genome.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: April 19, 2016
    Assignee: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure Le Ny, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Calcium Flux Agonists And Methods Therefor
    Publication number: 20150297572
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Application
    Filed: November 13, 2013
    Publication date: October 22, 2015
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Patrick Soon-Shiong, Anne-Laure Le Ny, Oleksandr Buzko
  • SMALL MOLECULE INHIBITORS OF INFLUENZA A RNA-DEPENDENT RNA POLYMERASE
    Publication number: 20140100228
    Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
    Type: Application
    Filed: December 11, 2013
    Publication date: April 10, 2014
    Applicant: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure LeNy, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
    Patent number: 8633198
    Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: January 21, 2014
    Assignee: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure Le Ny, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong